Polaris Partners is a Boston-based venture capital firm. Value Add VC tracks 1 company Polaris Partners has invested in and 1 venture round it took part in (0 as lead).
Polaris Partners key facts (as of )
| Fact | Value | Source |
|---|---|---|
| Headquarters | Boston, United States | Wikidata, September 16, 2026 |
| Founded | 1996 | Wikidata, September 16, 2026 |
| Type | Venture capital firm | Value Add VC classification |
| Partners and team | Ellie McGuire (Managing Partner); Alexandra Cantley (Managing Partner); Brian Chee (Managing Partner); Jon Flint (Founding Partner) 2 more in the Partners and team section | polarispartners.com, October 24, 2026 |
| Funds tracked | 1 | Funds table on this page (each fund cites its source) |
| Venture rounds tracked | 1 (led 0, joined 1) 1 in the last 12 months | Recent deals table on this page (each round cites its source) |
| Portfolio companies tracked | 1 | Portfolio list on this page |
Polaris Partners overview
Polaris Partners is a Boston-based investment firm with nearly 30 years of experience backing healthcare and biotech companies.[1] The firm says it has funded more than 400 companies, with more than 100 exits and more than 50 IPOs.[1] Its healthcare investments cover digital health, care delivery and data science, and its life sciences investments cover therapeutics, platforms and genomics.[1] Affiliate funds include the Polaris Growth Fund, for profitable founder-owned technology companies, and the Polaris Innovation Fund, which backs early-stage academic research.[1] Founding Partners Terry McGuire and Jon Flint are joined by Managing Partners including Amy Schulman, Ellie McGuire, Alexandra Cantley and Brian Chee.[2]
Recent deals we track
1Track record: led 0 and participated in 1 of 1 tracked venture round · 1 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Oct 13, 2026 | Souffle Therapeutics | Series B | Participated | $135M | — | Fidelity InvestmentsunverifiedARCH Venture PartnersunverifiedBessemer Venture PartnersunverifiedJanus Henderson InvestorsunverifiedLeaps by BayerunverifiedPolaris PartnersunverifiedTemasekunverifiedVida VenturesunverifiedJuvia GroupTCG Crossover ManagementBB BiotechBalyasny Asset Management+5 more | FinancialContent |
Is this your firm? Get featured or correct your listing →
About Polaris Partners
Polaris Partners was founded in 1996 and is headquartered in Boston, United States.[Wikidata][Wikidata] Its partners and team include Ellie McGuire (Managing Partner), Alexandra Cantley (Managing Partner), Brian Chee (Managing Partner) and Jon Flint (Founding Partner).[polarispartners.com]
Polaris Partners partners and team
6- Ellie McGuire · Managing Partner (polarispartners.com)
- Alexandra Cantley · Managing Partner (polarispartners.com)
- Brian Chee · Managing Partner (polarispartners.com)
- Jon Flint · Founding Partner (polarispartners.com)
- Amy Schulman · Managing Partner (polarispartners.com)
- Terry McGuire · Founding Partner (polarispartners.com)
Polaris Partners profile
written 2026-10-24Polaris Partners is a Boston healthcare and biotech investment firm founded in 1996 that reports 400+ companies funded and 100+ exits.
What Polaris Partners does
Polaris Partners is an investment firm with nearly 30 years of experience backing healthcare and biotech companies, and its website lists offices in Boston, New York, San Francisco and Singapore.[1]
Polaris Partners reports its own track record as 400+ companies funded, 100+ exits, 50+ IPOs, 50+ repeat entrepreneurs and 60+ therapies to market.[1]
Polaris Partners says its life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics and genomics. Its healthcare portfolio companies target care delivery models such as digital health, consumer-centric businesses, patient and provider solutions, and data science and analytics.[1]
History
Funds
Polaris Partners X, L.P., a Delaware limited partnership based in Boston, filed a Form D/A signed on April 21, 2023 that reported $354,590,909 sold against a $355,000,000 total offering amount, with the first sale on February 11, 2022. The filing states the amounts include the general partner's capital commitment.[4]
Polaris Partners lists two affiliated funds on its site. The Polaris Growth Fund supports the growth and expansion of profitable, founder-owned technology companies, and the Polaris Innovation Fund aims to accelerate the commercial and therapeutic potential of early-stage academic research.[1],[5]
Polaris Partners' Innovation Fund page lists Robert Langer and Daniel Anderson as Scientific Advisory Committee Members. A testimonial on the firm's homepage describes Langer as co-founder of 20+ Polaris-backed companies.[5],[6]
People
Polaris Partners' team page lists Terry McGuire and Jon Flint as Founding Partners; Amy Schulman, Ellie McGuire, Alexandra Cantley and Brian Chee as Managing Partners; Amir Nashat as Entrepreneur Partner; Chen-Ee Lee as Partner; Gary Swart as Operating Partner; Dave Barrett as Senior Advisory Partner; and Harold Friedman as Chief Financial Officer.[3]
Polaris Partners says its team of founders, inventors and operators has 150+ years of investment experience partnering with entrepreneurs.[1]
Portfolio and notable investments
Soufflé Therapeutics announced an oversubscribed $135 million Series B financing on October 13, 2026, led by Juvia Group, with existing investors that include Polaris Partners, according to a Business Wire release. Amir Nashat, a Polaris Entrepreneur Partner, is Soufflé's Chief Executive Officer.[7],[5],[3]
Polaris Partners' Innovation Fund page lists portfolio companies including Amunix Pharmaceuticals, Ankyra, BeMe Health, ByHeart, Capstan Therapeutics, Dewpoint Therapeutics, Kallyope, Nomad Health, QurAlis, Satellite Bio and SunBird Bio.[5]
Exits
Polaris Partners' Innovation Fund page marks Amunix Pharmaceuticals as acquired by Sanofi and Sesh Therapy as acquired by Caraway, and lists Kronos Bio with the Nasdaq ticker KRON. The page gives no deal dates or prices.[5]
Strategy
Recent changes
- Oct 13, 2026Oct 13, 2026Invested in Souffle Therapeutics (Series B, $135M) FinancialContent
- Oct 22, 2025Oct 22, 2025New fund: Polaris Partners Fund XI (target $500M) SEC EDGAR Form D
Funds
1| Fund | Vintage | Size | Strategy | Source |
|---|---|---|---|---|
| Polaris Partners Fund XI | 2025 | target $500M | Flagship | As of Oct 20, 2026SEC EDGAR Form D |
Portfolio
1 totalCo-Investors
6Similar Firms
overlapping sector, stage or regionValue Add Research
Latest Pulse
- Oct 13, 2026TRexBio Closes $116.7M IPO, Lilly Eyes Bigger StakeTRexBio closed its IPO on Oct. 13, selling 8.33 million shares at $14 for about $116.7 million, with largest shareholder Eli Lilly signaling interest in raising its stake.→
- Oct 13, 2026Souffle Therapeutics Raises $135M For RNA TherapiesSouffle Therapeutics closed an oversubscribed $135 million Series B led by Juvia Group on Oct. 13 to push its RNA-delivery platform's first three programs toward the clinic.→
Polaris Partners FAQ
What stage does Polaris Partners invest at?
In the rounds Value Add VC tracks, Polaris Partners' deals were most often Series B (1).
Who are the partners at Polaris Partners?
Polaris Partners' partners and team include Ellie McGuire (Managing Partner), Alexandra Cantley (Managing Partner), Brian Chee (Managing Partner), Jon Flint (Founding Partner), Amy Schulman (Managing Partner) and Terry McGuire (Founding Partner), according to polarispartners.com.
What companies has Polaris Partners backed?
Companies Value Add VC tracks as Polaris Partners investments include Souffle Therapeutics.
Where is Polaris Partners based?
Polaris Partners is headquartered in Boston, United States and was founded in 1996, according to Wikidata.
Who does Polaris Partners co-invest with most?
In the rounds Value Add tracks, Polaris Partners most often invests alongside ARCH Venture Partners (1 shared deal), Bessemer Venture Partners (1 shared deal), Fidelity Investments (1 shared deal), Janus Henderson Investors (1 shared deal), Temasek (1 shared deal).
References
researched 2026-10-24Sources & methodologyshow
- SEC EDGAR Form Dprimary source1 fact
- FinancialContentresearch database1 fact
- polarispartners.comValue Add VC data6 facts
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.